Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Arq. ciências saúde UNIPAR ; 26(3): 1398-1411, set-dez. 2022.
Article in Portuguese | LILACS | ID: biblio-1414511

ABSTRACT

Pelas características anatômicas e fisiológicas dos rins, a lesão renal aguda tem sua origem nefrotóxica pela alta circulação local, o que favorece a alta concentração de substâncias tóxicas e seus metabólitos no tecido. A lesão renal aguda é uma complicação comum em internações hospitalares e principalmente em internações em unidades de terapia intensiva. A ciclofosfamida, um quimioterápico utilizado no tratamento de doenças autoimunes e neoplasias sólidas, pode causar nefrotoxicidade com disfunção glomerular e tubular. O uso de plantas medicinais, pelas suas potentes ações antioxidantes, tem sido usado para prevenção ou tratamento de lesões celulares induzidas pelo desequilíbrio entre enzimas antioxidantes e oxidantes. Por esse motivo, o objetivo do experimento foi avaliar o potencial efeito protetor da Echinodorus grandiflorus na prevenção da nefrotoxidade induzida pela ciclofosfamida. Para isso, foi realizado o experimento com a utilização de 35 ratos machos, Wistar, divididos em seis grupos experimentais, sendo administrado a ciclofosfamida na dose de 150mg/kg nos grupos G2 a G6 e diferentes doses da Echinodorus grandiflorus, com posterior análise de parâmetros sanguíneos e histológicos. A administração de ciclofosfamida na dose de 150mg/kg de massa corporal, em dose única, foi capaz de induzir a nefrotoxicidade aguda em todos os ratos. O extrato bruto de Echinodorus grandiflorus apresentou potencial efeito renoprotetor ao uso da ciclofosfamida, na dose de 300mg/kg de massa corporal, sendo possível observar redução dos efeitos nefrotóxicos do quimioterápico, pela redução dos danos tubulares e pela diminuição dos espaços capsulas, nitidamente encontradas alterados no grupo que recebeu apenas ciclofosfamida, denotando resultados promissores para utilização desta planta medicinal na prevenção da nefrotoxicidade induzida pelo fármaco. Contudo, novos estudos dos efeitos renoprotetor do chapéu de couro, poderão elucidar os mecanismos envolvidos na ação do extrato bruto do chapéu de couro. A utilização de extrato bruto de plantas medicinais torna-se um adjuvante aos tratamentos pelo baixo custo e pela facilidade de acesso das diferentes populações as plantas desde que devidamente orientados pelos profissionais habilitados.


Due to the anatomical and physiological characteristics of the kidneys, acute kidney injury has its nephrotoxic origin due to the high local circulation, which favors the high concentration of toxic substances and their metabolites in the tissue. Acute kidney injury is a common complication in hospital admissions and especially in intensive care unit admissions. Cyclophosphamide, a chemotherapy drug used in the treatment of autoimmune diseases and solid neoplasms, can cause nephrotoxicity with glomerular and tubular dysfunction. The use of medicinal plants, due to their potent antioxidant actions, has been used for the prevention or treatment of cellular injuries induced by the imbalance between antioxidant and oxidant enzymes. For this reason, the aim of the experiment was to evaluate the potential protective effect of Echinodorus grandiflorus in preventing cyclophosphamide-induced nephrotoxicity. For this, the experiment was carried out with the use of 35 male Wistar rats, divided into six experimental groups, being administered cyclophosphamide at a dose of 150mg/kg in groups G2 to G6 and different doses of Echinodorus grandiflorus, with subsequent analysis of parameters blood and histology. The administration of cyclophosphamide at a dose of 150mg/kg of body weight, in a single dose, was able to induce acute nephrotoxicity in all rats. The crude extract of Echinodorus grandiflorus showed a potential renoprotective effect with the use of cyclophosphamide, at a dose of 300mg/kg of body mass, and it was possible to observe a reduction in the nephrotoxic effects of the chemotherapy, due to the reduction of tubular damage and the reduction of capsule spaces, clearly found altered in the group that received only cyclophosphamide, showing promising results for the use of this medicinal plant in the prevention of drug-induced nephrotoxicity. However, further studies of the renoprotective effects of the leather hat may elucidate the mechanisms involved in the action of the crude extract of the leather hat. The use of raw extract of medicinal plants becomes an adjuvant to treatments due to the low cost and ease of access of different populations to plants, provided that they are properly guided by qualified professionals.


Debido a las características anatómicas y fisiológicas de los riñones, la lesión renal aguda tiene su origen nefrotóxico por la elevada circulación local, que favorece la alta concentración de sustancias tóxicas y sus metabolitos en el tejido. La lesión renal aguda es una complicación frecuente en los ingresos hospitalarios y principalmente en las unidades de cuidados intensivos. La ciclofosfamida, un quimioterápico utilizado en el tratamiento de enfermedades autoinmunes y neoplasias sólidas, puede causar nefrotoxicidad con disfunción glomerular y tubular. El uso de plantas medicinales, debido a sus potentes acciones antioxidantes, se ha utilizado para la prevención o el tratamiento de lesiones celulares inducidas por el desequilibrio entre enzimas antioxidantes y oxidantes. Por este motivo, el objetivo del experimento era evaluar el posible efecto protector del Echinodorus grandiflorus en la prevención de la nefrotoxicidad inducida por la ciclofosfamida. Para ello, se realizó el experimento utilizando 35 ratas Wistar macho, divididas en seis grupos experimentales, administrándoseles ciclofosfamida a una dosis de 150mg/kg en los grupos G2 a G6 y diferentes dosis de Echinodorus grandiflorus, con posterior análisis de sangre y parámetros histológicos. La administración de ciclofosfamida a una dosis de 150mg/kg de masa corporal, en dosis única, fue capaz de inducir nefrotoxicidad aguda en todas las ratas. El extracto crudo de Echinodorus grandiflorus presentó un potencial efecto renoprotector al uso de ciclofosfamida, a una dosis de 300mg/kg de masa corporal, siendo posible observar una reducción de los efectos nefrotóxicos de la quimioterapia, por la reducción del daño tubular y por la disminución de los espacios capsulares, encontrándose claramente alterados en el grupo que recibió solamente ciclofosfamida, denotando resultados promisorios para el uso de esta planta medicinal en la prevención de la nefrotoxicidad inducida por el fármaco. Sin embargo, nuevos estudios sobre los efectos renoprotectores del sombrero de cuero podrían dilucidar los mecanismos implicados en la acción del extracto crudo de sombrero de cuero. El uso de extractos crudos de plantas medicinales se convierte en un coadyuvante de los tratamientos por su bajo coste y la facilidad de acceso de las diferentes poblaciones a las plantas desde que son guiadas adecuadamente por profesionales cualificados.


Subject(s)
Animals , Rats , Cyclophosphamide/analysis , Alismataceae/toxicity , Acute Kidney Injury/drug therapy , Plants, Medicinal/drug effects , Body Weight/drug effects , Pharmaceutical Preparations/analysis , Mesna/toxicity , Rats, Wistar
2.
J Int Adv Otol ; 14(1): 63-67, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29092802

ABSTRACT

OBJECTIVE: MESNA (Sodium-2-mercaptoethanesulfonate) is a mucolytic substance that is used for chemically assisted tissue dissection in various surgical operations. The aim of this study was to address the issue of possible neurotoxicity from topical administration of MESNA solution on the facial nerve. We used different concentrations of MESNA solution and evaluated their effects on facial nerve by histopathological and functional analysis. MATERIALS AND METHODS: These groups were the saline administered group (control) (3 rats, 6 facial nerves), the 25% MESNA solution group (3 rats, 6 facial nerves), and the 100% MESNA solution group (3 rats, 6 facial nerves). Under general anesthesia (ketamine 150 mg/kg, xylocaine 4 mg/kg), the bilateral facial nerves of rats were dissected. The saline, 25% MESNA, and 100% MESNA solutions. Facial nerve functions of the rats were evaluated using mustachewhisker and blink reflex scores at day 20 days. On day 20, the rats were sacrificed and the buccal and marginal mandibular branches of the facial nerve were removed. The specimens were examined in terms of inflammation, granulation tissue, and foreign body reaction formation around the nerve. The functional and histopathological changes on facial nerves were compared between groups. RESULTS: Mustache and blink reflex scores of the rats were 5 (normal) in both the control and study groups. There were no statistically significant differences between the three groups in terms of facial nerve functions (p=1.00). On histopathologic examination, the 25% and 100% MESNA groups had significantly more inflammation compared with the control group (p=0.038 and p=0.007, respectively). There were no statistically significant differences between the 25% and 100% MESNA groups in term of inflammation (p > 0.05). There were no statistically significant differences between the three groups in terms of foreign body reaction formation (p > 0.05). CONCLUSION: Topical administration of MESNA solution onto the facial nerve causes increased inflammation in both the 25% and 100% concentrations. Nevertheless, it does not cause any facial nerve dysfunction.


Subject(s)
Facial Nerve/drug effects , Facial Nerve/surgery , Mesna/adverse effects , Administration, Topical , Animal Experimentation , Animals , Facial Nerve/pathology , Facial Nerve/ultrastructure , Inflammation/chemically induced , Inflammation/pathology , Mesna/administration & dosage , Mesna/toxicity , Protective Agents/adverse effects , Protective Agents/toxicity , Rats , Rats, Wistar
3.
Nanotoxicology ; 7(2): 192-201, 2013 Mar.
Article in English | MEDLINE | ID: mdl-22263968

ABSTRACT

Incorporation of gold nanoparticles (AuNPs) into consumer products is increasing; however, there is a gap in available toxicological data to determine the safety of AuNPs. In this study, we utilised the embryonic zebrafish to investigate how surface functionalisation and charge influence molecular responses. Precisely engineered AuNPs with 1.5 nm cores were synthesised and functionalized with three ligands: 2-mercaptoethanesulfonic acid (MES), N,N,N-trimethylammoniumethanethiol (TMAT), or 2-(2-(2-mercaptoethoxy)ethoxy)ethanol. Developmental assessments revealed differential biological responses when embryos were exposed to the functionalised AuNPs at the same concentration. Using inductively coupled plasma-mass spectrometry, AuNP uptake was confirmed in exposed embryos. Following exposure to MES- and TMAT-AuNPs from 6 to 24 or 6 to 48 h post fertilisation, pathways involved in inflammation and immune response were perturbed. Additionally, transport mechanisms were misregulated after exposure to TMAT and MES-AuNPs, demonstrating that surface functionalisation influences many molecular pathways.


Subject(s)
Gene Expression Regulation, Developmental/drug effects , Gold/toxicity , Metal Nanoparticles/toxicity , Zebrafish/genetics , Animals , Embryo, Nonmammalian/drug effects , Embryo, Nonmammalian/metabolism , Gene Expression Profiling , Gene Regulatory Networks/drug effects , Gold/chemistry , Gold/metabolism , Mass Spectrometry , Mercaptoethanol/analogs & derivatives , Mercaptoethanol/toxicity , Mesna/toxicity , Metal Nanoparticles/chemistry , Particle Size , Quaternary Ammonium Compounds/toxicity , Sulfhydryl Compounds/toxicity , Surface Properties , Time Factors , Zebrafish/embryology , Zebrafish/metabolism
4.
Comp Biochem Physiol C Toxicol Pharmacol ; 155(2): 269-74, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21946249

ABSTRACT

As the number of products containing nanomaterials increase, human exposure to nanoparticles (NPs) is unavoidable. Presently, few studies focus on the potential long-term consequences of developmental NP exposure. In this study, zebrafish embryos were acutely exposed to three gold NPs that possess functional groups with differing surface charge. Embryos were exposed to 50 µg/mL of 1.5 nm gold nanoparticles (AuNPs) possessing negatively charged 2-mercaptoethanesulfonic acid (MES) or neutral 2-(2-(2-mercaptoethoxy)ethoxy)ethanol (MEEE) ligands or 10 µg/mL of the AuNPs possessing positively charged trimethylammoniumethanethiol (TMAT). Both MES- and TMAT-AuNP exposed embryos exhibited hypo-locomotor activity, while those exposed to MEEE-AuNPs did not. A subset of embryos that were exposed to 1.5 nm MES- and TMAT-AuNPs during development from 6 to 120 h post fertilization was raised to adulthood. Behavioral abnormalities and the number of survivors into adulthood were evaluated at 122 days post fertilization. We found that both treatments induced abnormal startle behavior following a tap stimulus. However, the MES-AuNPs exposed group also exhibited abnormal adult behavior in the light and had a lower survivorship into adulthood. This study demonstrates that acute, developmental exposure to 1.5 nm MES- and TMAT-AuNPs, two NPs differing only in the functional group, affects larval behavior, with behavioral effects persisting into adulthood.


Subject(s)
Embryo, Nonmammalian/drug effects , Gold/toxicity , Metal Nanoparticles/toxicity , Motor Activity/drug effects , Zebrafish/physiology , Animals , Embryo, Nonmammalian/embryology , Gold/chemistry , Humans , Larva/drug effects , Larva/physiology , Mesna/chemistry , Mesna/toxicity , Metal Nanoparticles/chemistry , Quaternary Ammonium Compounds/chemistry , Quaternary Ammonium Compounds/toxicity , Sulfhydryl Compounds/chemistry , Sulfhydryl Compounds/toxicity , Time Factors , Zebrafish/embryology
5.
Ann Dermatol Venereol ; 138(4): 307-10, 2011.
Article in French | MEDLINE | ID: mdl-21497258

ABSTRACT

BACKGROUND: MINE chemotherapy is used to treat refractory Hodgkin's disease. Cutaneous adverse effects of MINE regimen are uncommon and chiefly consist of erythema and oedema of the extremities. More recently, a number of cases of panniculitis and subcutaneous inflammatory oedema have been described. OBSERVATION: We report the case of a 17-year-old girl developing acute and painful oedema of the limbs with panniculitis of the trunk. This incident was associated with inflammatory lesions of mucous membrane, in particularly in the genital area and on the tongue. These signs occurred 7 days after initiation of MINE chemotherapy, with no other drugs being introduced. A drug-induced reaction was suspected due to the absence of any other aetiology, particularly infectious disease. The condition gradually improved with symptomatic pain therapy. The patient's chemotherapy was subsequently modified. DISCUSSION: The chronology of the symptoms, spontaneous improvement after the end of treatment, and the absence of other potential causative factors resulted in a hypothesis of a cutaneous adverse reaction to the MINE regimen. The signs could be due to capillary leak syndrome resulting from the toxicity of vinorelbine on endothelial cells. Dermatologists should be aware of these cutaneous adverse effects and of the inflammatory lesions of mucous membrane newly described herein.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/toxicity , Drug Eruptions/diagnosis , Hodgkin Disease/drug therapy , Mucositis/chemically induced , Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Edema/chemically induced , Etoposide/therapeutic use , Etoposide/toxicity , Female , Glossitis/chemically induced , Glossitis/diagnosis , Humans , Hyperalgesia/chemically induced , Ifosfamide/therapeutic use , Ifosfamide/toxicity , Mesna/therapeutic use , Mesna/toxicity , Mitoxantrone/therapeutic use , Mitoxantrone/toxicity , Mucositis/diagnosis , Panniculitis/chemically induced , Panniculitis/diagnosis
6.
Cell Biol Toxicol ; 23(5): 303-12, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17225077

ABSTRACT

Cyclophosphamide (CP) and ifosfamide (IF) are widely used antineoplastic agents, but their side-effect of hemorrhagic cystitis (HC) is still encountered as an important problem. Acrolein is the main molecule responsible of this side-effect and mesna (2-mercaptoethane sulfonate) is the commonly used preventive agent. Mesna binds acrolein and prevent its direct contact with uroepithelium. Current knowledge provides information about the pathophysiological mechanism of HC: several transcription factors and cytokines, free radicals and non-radical reactive molecules, as well as poly(adenosine diphosphate-ribose) polymerase (PARP) activation are now known to take part in its pathogenesis. There is no doubt that HC is an inflammatory process, including when caused by CP. Thus, many cytokines such as tumor necrosis factor (TNF) and the interleukin (IL) family and transcription factors such as nuclear factor-kappaB (NF-kappaB) and activator protein-1 (AP-1) also play a role in its pathogenesis. When these molecular factors are taken into account, pathogenesis of CP-induced bladder toxicity can be summarized in three steps: (1) acrolein rapidly enters into the uroepithelial cells; (2) it then activates intracellular reactive oxygen species and nitric oxide production (directly or through NF-kappaB and AP-1) leading to peroxynitrite production; (3) finally, the increased peroxynitrite level damages lipids (lipid peroxidation), proteins (protein oxidation) and DNA (strand breaks) leading to activation of PARP, a DNA repair enzyme. DNA damage causes PARP overactivation, resulting in the depletion of oxidized nicotinamide-adenine dinucleotide and adenosine triphosphate, and consequently in necrotic cell death. For more effective prevention against HC, all pathophysiological mechanisms must be taken into consideration.


Subject(s)
Antineoplastic Agents/adverse effects , Cyclophosphamide/adverse effects , Cystitis/chemically induced , Hemorrhage/chemically induced , Ifosfamide/adverse effects , Poly(ADP-ribose) Polymerases/metabolism , Acrolein/toxicity , Cell Death/drug effects , Cystitis/metabolism , Cytokines/metabolism , DNA Damage/drug effects , Enzyme Activation , Hemorrhage/metabolism , Humans , Lipid Peroxidation/drug effects , Mesna/toxicity , Nitrogen/metabolism , Oxygen/metabolism , Reactive Oxygen Species/metabolism , Transcription Factors/metabolism
7.
IDrugs ; 7(1): 64-9, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14730469

ABSTRACT

BioNumerik Pharmacology Inc, Baxter Oncology GmbH (formerly ASTA Medica AG) and Grelan Pharmaceutical Co Ltd are developing BNP-7787 for the potential reduction of toxicity associated with cisplatin and carboplatin treatment in cancer patients.


Subject(s)
Antiemetics/therapeutic use , Antineoplastic Agents/adverse effects , Mesna/analogs & derivatives , Mesna/therapeutic use , Vomiting/chemically induced , Vomiting/drug therapy , Animals , Antiemetics/adverse effects , Antiemetics/pharmacokinetics , Antiemetics/toxicity , Clinical Trials, Phase I as Topic , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Humans , Mesna/adverse effects , Mesna/pharmacokinetics , Mesna/toxicity , Structure-Activity Relationship , Vomiting/prevention & control
8.
Reprod Toxicol ; 17(6): 699-708, 2003.
Article in English | MEDLINE | ID: mdl-14613822

ABSTRACT

Ifosfamide, a chemotherapeutic agent with a broad spectrum of antineoplastic activity, is concurrently administered with the uroprotectant mesna to avoid the urotoxic effect. This study was undertaken to investigate possible effects of ifosfamide-mesna treatment on the testes and semen characteristics in rabbits. Sexually mature New Zealand White male rabbits received intravenously 10 weekly treatments of ifosfamide+mesna (groups A, B and C received 30, 45 or 60 mg/kg of body weight ifosfamide+6, 9 or 12 mg/kg of body weight mesna, respectively, followed by a second equal dose of mesna 4 h later); groups MA, MB and MC received mesna alone at corresponding doses; and group S received normal saline. Reproductive organ weight as well as various qualitative and quantitative parameters of testis histology (minor diameter of seminiferous tubules, the most advanced germ cell type in seminiferous tubule identified in cross sections, and the number of germ cells per stage 1 seminiferous tubule cross section) were determined 1 day and 20 weeks after the treatment period, while semen quality (sperm count, sperm morphology and sperm progressive motility) and libido were evaluated on a weekly basis. Changes were noted only in the ifosfamide+mesna treated animals. One day after treatment, reproductive organ weights were decreased in groups A-C. Major histopathological lesions were not found; however, quantitative histological endpoints were altered in groups A-C. Transient oligospermia and teratozoospermia were noted in groups B and C, while asthenozoospermia was observed in group C only. The time course of these sperm alterations suggested possible bioaccumulation and residual activity of ifosfamide. Libido remained normal. The decrease in reproductive organ weights persisted in groups B and C to 20 weeks after treatment but only one quantitative histological endpoint, the number of the round spermatids per stage 1 seminiferous tubule cross section, remained decreased in group C. These results suggest that subchronic treatment with ifosfamide-mesna suppressed spermatogenesis and epididymal sperm maturation in the rabbit. Germinal epithelium recovery was not complete because although sperm characteristics returned to pretreatment values, not all histological alterations were ameliorated.


Subject(s)
Antineoplastic Agents, Alkylating/toxicity , Expectorants/toxicity , Ifosfamide/toxicity , Mesna/toxicity , Semen/drug effects , Testis/drug effects , Animals , Body Weight/drug effects , Drug Combinations , Genitalia, Male/drug effects , Genitalia, Male/growth & development , Germ Cells/drug effects , Male , Organ Size/drug effects , Rabbits , Seminiferous Tubules/drug effects , Seminiferous Tubules/pathology , Sexual Behavior, Animal/drug effects , Sperm Count , Sperm Motility/drug effects , Testis/pathology
9.
Cancer Chemother Pharmacol ; 52 Suppl 1: S3-15, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12819940

ABSTRACT

Any approach applied to drug discovery and development by the medical community and pharmaceutical industry has a direct impact on the future availability of improved, novel, and curative therapies for patients with cancer. By definition, drug discovery is a complex learning process whereby research efforts are directed toward uncovering and assimilating new knowledge to create and develop a drug for the purpose of providing benefit to a defined patient population. Accordingly, a highly desirable technology or approach to drug discovery should facilitate both effective learning and the application of newly discovered observations that can be exploited for therapeutic benefit. However, some believe that drug discovery is largely accomplished by serendipity and therefore appropriately addressed by screening a large number of compounds. Clearly, this approach has not generated an abundance of new drugs for cancer patients and suggests that a tangibly different approach in drug discovery is warranted. We employ an alternative approach to drug discovery, which is based on the elucidation and exploitation of biological, pharmacological, and biochemical mechanisms that have not been previously recognized or fully understood. Mechanism-based drug discovery involves the combined application of physics-based computer simulations and laboratory experimentation. There is increasing evidence that agreement between simulations based on the laws of physics and experimental observations results in a higher probability that such observations are more accurate and better understood as compared with either approach used alone. Physics-based computer simulation applied to drug discovery is now considered by experts in the field to be one of the ultimate methodologies for drug discovery. However, the ability to perform truly comprehensive physics-based molecular simulations remains limited by several factors, including the enormous computer-processing power that is required to perform the formidable mathematical operations and data processing (e.g. memory bandwidth, data storage and retrieval). Another major consideration is the development of software that can generate an appropriate and increasingly complex physical representation of the atomic arrangements of biological systems. During the past 17 years, we have made tremendous progress in addressing some of these obstacles by developing and optimizing physics-based computer programs for the purpose of obtaining increasingly accurate and precise information and by improving the speed of computation. To perform physics-based simulations that involve complex systems of biological and pharmaceutical interest, we have developed methods that enable us to exceed Moore's law. This has been accomplished by parallel processing as well as other methods that have enabled us to study more complex and relevant molecular systems of interest. This paper provides an overview of our approach to drug discovery and describes a novel drug, currently in clinical development, which has directly resulted from the application of this approach.


Subject(s)
Computer Simulation , Drug Design , Mesna/analogs & derivatives , Mesna/chemistry , Protective Agents/chemistry , Animals , Clinical Trials, Phase I as Topic , Humans , Lethal Dose 50 , Mesna/therapeutic use , Mesna/toxicity , Models, Chemical , Neurotoxicity Syndromes/prevention & control , Protective Agents/therapeutic use , Protective Agents/toxicity
10.
Eur J Haematol Suppl ; 64: 21-7, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11486396

ABSTRACT

Treatment of early relapsing or resistant non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) remains problematic. High-dose chemotherapy followed by autologous peripheral blood stem cell (PBSC) transplantation improves the prognosis for patients in response following standard dose regimens. We adopted the strategy of using salvage chemotherapy to debulk disease and simultaneously mobilize stem cells. We used regimens based on ifosfamide and etoposide because these drugs are not usually used as the front-line treatment. Twenty-seven patients with NHL received MINE chemotherapy (mesna and ifosfamide 1330 mg/m2 and etoposide 65 mg/m2 i.v. days 1-3, and mitoxantrone 8 mg/m2 i.v. day 1). The same schedule, but higher doses were used for PBSC stimulation (mesna, ifosfamide 1700 mg/m2, etoposide 175 mg/m2, mitoxantrone 10 mg/m2). Forty-six patients with HD received VIM chemotherapy (mesna, ifosfamide 1200 mg/m2 i.v. days 1-5, etoposide 90 mg/m2 i.v. days 1, 3, and 5, methotrexate 30 mg/m2 i.v. days 1 and 5). After both VIM and high dose MINE, chemotherapy for mobilization was followed by G-CSF administered at a dose 5-16 micrograms/kg/day depending on the clinicians judgement of the patient's pretreatment. Complete response after VIM and MINE were 39% and 38%, respectively; partial response (PR) rates were 17% and 29%, and stable disease (SD) 25% and 4%, respectively. In both groups, patients with relapsing disease had better responses than did those with primary progressive disease. Both regimens exhibited excellent mobilizing capacity. We performed 213 aphereses with a median 3 per patient starting on either day 13 as a median for VIM, or on day 12 as a median for MINE. In the majority of patients, the collection started in the time interval median +/- 1 day (n = 62, 85%). The median yields were 10.6 x 10(6) CD34+ cells/kg and 53.1 x 10(4) CFU-GM/kg for VIM, and 13.3 x 10(6) CD34+ cells/kg and 54.5 x 10(4) CFU-GM/kg for MINE. We collected at least 2.5 x 10(6) CD34+ cells/kg in all but six patients (8%), and the harvested amount of CD34+ cells was less than 1.0 x 10(6)/kg in only two patients (3%). The toxicity of VIM and MINE was minimal and chemotherapy-induced trombocytopenia did not occur with PBSC collection.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Etoposide/administration & dosage , Hematopoietic Stem Cell Mobilization/methods , Ifosfamide/administration & dosage , Lymphoma/drug therapy , Salvage Therapy/methods , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/toxicity , Etoposide/toxicity , Female , Graft Survival , Hematopoietic Stem Cell Transplantation , Humans , Ifosfamide/toxicity , Kinetics , Lymphoma/diagnosis , Male , Mesna/administration & dosage , Mesna/toxicity , Methotrexate/administration & dosage , Methotrexate/toxicity , Middle Aged , Mitoxantrone/administration & dosage , Mitoxantrone/toxicity , Prognosis , Treatment Outcome
11.
Acta Otolaryngol ; 119(6): 685-9, 1999.
Article in English | MEDLINE | ID: mdl-10587002

ABSTRACT

Mesna (Mistabron) is a mucolytic substance that is also used for chemically assisted dissection during cholesteatoma surgery. The present animal study aims to evaluate its possible ototoxic side effects. To this end, the right tympanic cavity of 9 guinea pigs was filled with either 20% mesna or 10% neomycin (serving as a positive control), while the left tympanic cavity was filled with saline (serving as a negative control). One week after administration, the inner ears were dissected out and further processed for morphological evaluation by means of either interference contrast microscopy or scanning electron microscopy. No macroscopic signs of middle ear inflammation were observed in any of the ears treated. Whereas damage was obvious in all neomycin-treated specimens, the morphology of both saline- and mesna-treated inner ears was unaffected. These findings led us to conclude that, at least on a morphological basis, no indications are at hand to assume ototoxic effects of this mucolytic substance due to a single application during cholesteatoma surgery.


Subject(s)
Expectorants/toxicity , Hair Cells, Auditory/drug effects , Mesna/toxicity , Administration, Topical , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/toxicity , Chi-Square Distribution , Expectorants/administration & dosage , Female , Guinea Pigs , Hair Cells, Auditory/ultrastructure , Male , Mesna/administration & dosage , Microscopy, Electron, Scanning , Neomycin/administration & dosage , Neomycin/toxicity , Surface Properties
12.
Ann Oncol ; 10(9): 1087-94, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10572607

ABSTRACT

BACKGROUND: The aim of this study was to assess the pharmacology, toxicity and activity of high-dose ifosfamide mesna +/- GM-CSF administered by a five-day continuous infusion at a total ifosfamide dose of 12-18 g/m2 in adult patients with advanced sarcomas. PATIENTS AND METHODS: Between January 1991 and October 1992 32 patients with advanced or metastatic sarcoma were entered the study. Twenty-seven patients were pretreated including twenty-three with prior ifosfamide at less than 8 g/m2 total dose/cycle. In 25 patients (27 cycles) extensive pharmacokinetic analyses were performed. RESULTS: The area under the plasma concentration-time curve (AUC) for ifosfamide increased linearly with dose while the AUC's of the metabolites measured in plasma by thin-layer chromatography did not increase with dose, particularly that of the active metabolite isophosphoramide mustard. Furthermore the AUC of the inactive carboxymetabolite did not increase with dose. Interpatient variability of pharmacokinetic parameters was high. Dose-limiting toxicity was myelosuppression at 18 g/m2 total dose with grade 4 neutropenia in five of six patients and grade 4 thrombocytopenia in four of six patients. Therefore the maximum tolerated dose was considered to be 18 g/m2 total dose. There was one CR and eleven PR in twenty-nine evaluable patients (overall response rate 41%). CONCLUSION: Both the activation and inactivation pathways of ifosfamide are non-linear and saturable at high-doses although the pharmacokinetics of the parent drug itself are dose linear. Ifosfamide doses greater than 14-16 g/m2 per cycle appear to result in a relative decrease of the active metabolite isophosphoramide mustard. These data suggest a dose-dependent saturation or even inhibition of ifosfamide metabolism by increasing high dose ifosfamide and suggest the need for further metabolic studies.


Subject(s)
Antineoplastic Agents, Alkylating/pharmacokinetics , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacokinetics , Ifosfamide/pharmacokinetics , Mesna/pharmacokinetics , Protective Agents/pharmacokinetics , Sarcoma/drug therapy , Adult , Aged , Antineoplastic Agents, Alkylating/blood , Antineoplastic Agents, Alkylating/toxicity , Antineoplastic Agents, Alkylating/urine , Area Under Curve , Dose-Response Relationship, Drug , Female , Humans , Ifosfamide/blood , Ifosfamide/toxicity , Ifosfamide/urine , Male , Mesna/toxicity , Middle Aged , Prodrugs/pharmacokinetics , Protective Agents/toxicity , Remission Induction , Time Factors
14.
Rev. Inst. Nac. Cancerol. (Méx.) ; 40(supl.1): 34-9, 1994. tab
Article in Spanish | LILACS | ID: lil-147845

ABSTRACT

Los casos de carcinoma cervicouterino se diagnostican en la mayoría de las pacientes en etapas localmente avanzadas. Esto evita el abordaje quirúrgico. La quimioterapia combinada neoadyuvante ha demostrado reducción tumoral en más de la mitad de los casos tratados. En el Instituto Nacional de Cancerología, elaboramos un estudio fase II con objeto de determinar la eficacia y la toxicidad de la combinación de ifosfamida+mesna+carboplatino. También se evaluó la posibilidad de intervenir quirúrgicamente a las enfermas con carcinoma cervicouterino etapa IIB. Se incluyeron 20 pacientes sin tratamiento previo y con edad promedio de 42 años. Todas recibieron tres ciclos de quimioterapia cada cuatro semanas con carboplatino 300 mg/m² el día 1+ifosfamida 3g/m²/día por dos días en infusión contínua de 24 horas; mesna 600mg por vía intravenosa (bolo) directo antes de ifosfamida; 3,000 mg en la solución de la ifosfamida en infusión de 24 horas por dos días. Al término de ésta se administró 1,500 mg de mesna en 1,00 ml de solución glucosada en infusión de 12 horas. Se obtuvieron cuatro respuestas completas y nueve parciales; tres pacientes cursaron con enfermedad estable y cuatro progresaron. En dos enfermas sometidas a cirugía, los especímenes mostraron: carcinoma in situ residual en una mujer y en la otra no hubo actividad tumoral. De 18 pacientes que recibieron radioterapia posterior a la quimioterapia, 13 tuvieron respuesta completa, una mostró respuesta parcial y cuatro progresaron. La toxicidad para 54 ciclos de quimioterapia fue predominantemente medular; neutropenia grado 1-2 (6 por ciento), grado 3-4 (62 por ciento); plaquetopenia grado 0 (90 por ciento), grado 1-2 (44 por ciento) y grado 3 (4 por ciento). No se observó ningún proceso séptico asociado a la neutropenia. Se presentó emesis grado 2-3 en el 42 por ciento y alopecia grado 3 en el 75 por ciento. El seguimiento promedio para todas la pacientes fue de 12 meses. El intervalo libre de progresión en 14 casos con respuesta completa (13 con quimioterapia+radioterapia y uno con quimioterapia+cirugía) fue de 14.3 meses promedio (extremos 6-19 meses). Los resultados obtenidos con esta combinación confirman un alto índice de respuestas objetivas (65 por ciento) y completas (20 por ciento) con toxicidad moderada. La quimioterapia neoadyuvante puede reducir suficientemente el volumen tumoral; esto permite la cirugía en pacientes tradicionalmente consideradas con enfermedad irresecable


Subject(s)
Adolescent , Adult , Humans , Female , Carboplatin/pharmacology , Carboplatin/toxicity , Dimethoate/pharmacology , Dimethoate/toxicity , Drug Therapy, Combination , Mesna/pharmacology , Mesna/toxicity , Uterine Cervical Neoplasms/diagnosis
15.
Rev. Inst. Nac. Cancerol. (Méx.) ; 40(supl.1): 59-61, 1994. tab
Article in Spanish | LILACS | ID: lil-147846

ABSTRACT

Existen grandes avances en el manejo de los linfomas; desafortunadamente un porcentaje variable de casos recaerán a regímenes de primera línea. Se informan los resultados preliminares de 17 pacientes con diagnóstico de linfoma de Hodgkin refractarios a manejo de primera línea o refractarios. El esquema utilizado fue cada 3-4 semanas: combinación de etopósido 100 mg/m² por tres días, platino 100 mg/m² e ifosfamida 5g/m² fraccionados en tres días, mesna al 20 por ciento de la dosis diaria de ifosfamida por tres dosis; y dexametasona de 20 a 40 mg cada 24 horas por tres días. Trece de los 17 pacientes fueron evaluables para eficacia (dos aún en tratamiento; los otros dos abandonaron la terapia) y 16 fueron evaluables para toxicidad en 74 ciclos administrados. Se obtuvieron 11 respuestas totales (84 por ciento): seis respuestas (46 por ciento) Äcon supervivencia libre de enfermedad mínima de dos meses y máxima de 11 mesesÄ y cinco respuestas parciales (38 por ciento). La toxicidad más frecuente y grave fue neutropenia grado 4 (20 por ciento) con dos muertos por septicemia y plaquetopenia grado 4 (7 por ciento). El resto de los efectos tóxicos fueron leves y reversibles. No se observó toxicidad vasical. Concluimos que el esquema utilizado es efectivo, pero conlleva toxicidad grave en una cuarta parte de los ciclos. Consideramos que es conveniente incluir factores estimulantes de colonias en este tratamiento


Subject(s)
Adult , Middle Aged , Humans , Male , Female , Dexamethasone/administration & dosage , Dexamethasone/therapeutic use , Dexamethasone/toxicity , Drug Therapy, Combination , Etoposide/administration & dosage , Etoposide/therapeutic use , Etoposide/toxicity , Hodgkin Disease/drug therapy , Hodgkin Disease/physiopathology , Ifosfamide/administration & dosage , Ifosfamide/therapeutic use , Ifosfamide/toxicity , Mesna/administration & dosage , Mesna/therapeutic use , Mesna/toxicity , Platinum/administration & dosage , Platinum/therapeutic use , Platinum/toxicity
17.
Drugs Exp Clin Res ; 14(7): 473-8, 1988.
Article in English | MEDLINE | ID: mdl-3149236

ABSTRACT

The action of arginine 2-mercaptoethane sulfonate in comparison with sodium 2-mercaptoethane sulfonate on cell growth and cell adhesion of a metastatic sub-line of murine melanoma (F10/B16) was investigated. The capability of the two compounds to interfere with the cytotoxicity of 4-hydroperoxycyclophosphamide and of cis-dichlorodiammineplatinum(II) in F10 cells was studied. The in vivo studies included the determination of acute and sub-acute toxicity of the two salts on mice. Very low toxicity and no significant differences between the two compounds were detected.


Subject(s)
Antineoplastic Agents/pharmacology , Arginine/analogs & derivatives , Mercaptoethanol/analogs & derivatives , Mesna/analogs & derivatives , Mesna/pharmacology , Tumor Cells, Cultured/drug effects , Animals , Arginine/pharmacology , Arginine/toxicity , Cell Division/drug effects , Cell Line , Drug Screening Assays, Antitumor , Male , Melanoma, Experimental , Mesna/toxicity , Mice
19.
Eur J Cancer Clin Oncol ; 18(12): 1377-87, 1982 Dec.
Article in English | MEDLINE | ID: mdl-6819957

ABSTRACT

Mesna is a pharmacologically unremarkable, physiologically largely inert and almost totally non-toxic thio compound. It is rapidly eliminated renally and only slightly permeates into tissues. It has been shown experimentally that the bladder damage inducible in the rat by administration of oxazaphosphorine cytostatics can be successfully prevented by quite small doses of mesna. The detoxifying action of mesna is limited to the kidneys and the efferent urinary tract. The systemic effects of the oxazaphosphorines, however, remain unaffected. This applies particularly to the curative oncocidal efficacy of these compounds. It has also been shown experimentally that mesna does not affect the curative effects of other cytostatic drugs (doxorubicin, BCNU, methotrexate, vincristine). The efficacy of the cardiac glycoside proscillaridin is also not impaired by mesna.


Subject(s)
Cyclophosphamide/toxicity , Mercaptoethanol/analogs & derivatives , Mesna/pharmacology , Urinary Bladder Diseases/chemically induced , Animals , Cyclophosphamide/therapeutic use , Dogs , Drug Interactions , Female , Ifosfamide/therapeutic use , Ifosfamide/toxicity , Kinetics , Lethal Dose 50 , Male , Mesna/therapeutic use , Mesna/toxicity , Mice , Neoplasms, Experimental/drug therapy , Proscillaridin/therapeutic use , Rats , Urinary Bladder Diseases/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...